Redona Therapeutics focuses on modulating functional non-coding RNA and targeting enzymes involved in RNA and DNA dysregulation to develop therapeutics for cancer and autoimmune diseases. By addressing the underlying mechanisms that disrupt cellular homeostasis, the company aims to create effective treatments that restore normal cellular function.
Funding
$89.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dysregulation of RNA and DNA processing and signaling mechanisms can disrupt cellular homeostasis, contributing to the development of serious diseases such as cancer and autoimmune disorders. Current treatments may not effectively target the underlying enzymatic dysfunctions that drive these diseases.
Solution
Redona Therapeutics is developing novel therapeutics by modulating functional non-coding RNA and targeting enzymes involved in RNA and DNA dysregulation. The company aims to restore normal cellular function by addressing the fundamental mechanisms that disrupt cellular homeostasis. By focusing on these enzymatic targets, Redona seeks to create effective treatments for cancer and autoimmune diseases. This approach offers a unique opportunity to intervene in the disease process at a molecular level.
Target Audience
The primary target audience includes patients suffering from cancer and autoimmune diseases, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Focus on modulating functional non-coding RNA.
- Targets enzymes involved in RNA and DNA dysregulation.
- Aims to restore normal cellular function.
- Develops therapeutics for cancer and autoimmune diseases.